Kiniksa Pharmaceuticals International, plc (KNSA) is in Healthcare, Drug Manufacturers - Specialty & Generic, based in United Kingdom, listed on NasdaqGS. Market cap 6.05B USD. 52-week range 35.20 to 82.94 USD. Trailing P/E 79.4. Data as of 2026-10-09.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 ...